Antiretroviral Prophylaxis for HIV-1 Prevention among Heterosexual Men and Women
By J. Baeten, D. Donnell, P. Ndase, N. Mugo, J. Campbell, Jonathan Wangisi, J. Tappero, E. Bukusi, C. Cohen, E. Katabira and 35 more. New England Journal of Medicine, 2012
3,037 citations recorded by the source corpus.
Introduction Antiretroviral pre-exposure prophylaxis (PrEP) reduces the incidence of acquisition of human immunodeficiency virus type 1 (HIV-1) in men who have sex with men and is a promising approach for preventing HIV-1 in heterosexual populations. Methods We conducted a randomized, three-arm trial of oral antiretroviral PrEP among heterosexual couples from Kenya and Uganda in which one member was HIV-1 seronegative and the other HIV-1 seropositive. Seronegative partners were randomly assigned to once-daily tenofovir (TDF), combination emtricitabine/tenofovir (FTC/TDF), or matching placebo and followed monthly for up to 36 months. At enrollment, HIV-1 seropositive partners were not eligible for antiretroviral therapy under national guidelines. All couples received standard HIV-1 treatment and prevention services, including individual and couples risk-reduction counseling and condoms. Results 4758 couples were enrolled; for 62%, the HIV-1 seronegative partner was male. For HIV-1 seropositive participants, the median CD4 count was 495 cells/μL (interquartile range 375–662). Of 82 post-randomization HIV-1 infections, 17 were among those assigned TDF (incidence 0.65 per 100 person-years), 13 among those assigned FTC/TDF (incidence 0.50 per 100 person-years), and 52 among those assigned placebo (incidence 1.99 per 100 person-years), indicating a 67% relative reduction in HIV-1 incidence for TDF (95% CI 44 to 81, p<0.001) and 75% for FTC/TDF (95% CI 55 to 87, p<0.001). HIV-1 protective effects of FTC/TDF and TDF were not significantly different (p=0.23), and both study medications significantly reduced HIV-1 incidence in both men and women. The rate of serious medical events was similar across the study arms. Conclusions Oral TDF and FTC/TDF provided substantial protection against HIV-1 acquisition in heterosexual men and women, with comparable efficacy of TDF and FTC/TDF. (Funded by the Bill and Melinda Gates Foundation; ClinicalTrials.gov number NCT00557245)
Subfields: Infectious Diseases, Virology
View Paper: https://www.semanticscholar.org/paper/013339b06a0ace42d74c1ed42ea7691752c7002c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- V. Fonner
- Sarah L Dalglish
- C. Kennedy
- G. Bolan
- K. O'reilly
- R. Baggaley
- Florence M. Koechlin
- J. Molina
Citations in the corpus
- Sexually Transmitted Diseases Treatment Guidelines, 2015 (2015, background): “In addition, one clinical trial involving IDUs (77) and one involving heterosexual HIV-discordant couples (75) demonstrated substantial efficacy and safety of daily oral PrEP with TDF alone when combined with repeated condom provision, sexual risk-reduction counseling, and the diagnosis and treatmen”
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women (2015, neutral): “(%)‡ 163 (3) 42 (4) 27 (3) 34 (3) 24 (2) 36 (4)”
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015, background): “Immune from natural infection 18 (9) 31 (15)”
- An observational study of preexposure prophylaxis uptake, sexual practices, and HIV incidence among men and transgender women who have sex with men (2014, neutral): “People who more often engaged in risky sexual practices and who had sexually transmitted infections were more likely to join the study, more likely to choose PrEP, and more likely to have sustained protective levels of PrEP use.”
- Effectiveness and safety of oral HIV preexposure prophylaxis for all populations (2016, methodology): “The finding that TDF and FTC/TDF have comparable effectiveness in meta-analysis is consistent with two clinical placebo-controlled trials that compared the regimens directly in heterosexual populations [32,47], and with one study comparing single and dual-agent PrEP [40].”